- Treatment of Hemophilia: On the Precipice of a RevolutionJanuary 01, 2017 | January-February 2017, Volume 14, Issue 1
Dr. Cuker talks about advances in the treatment of hemophilia and the potential for more effective and more convenient treatments and even cure, calling it an exciting time in hemophilia.
- FIXing Hemophilia B: Sustained Factor IX Expression of 30 Percent After Gene TherapyAugust 12, 2016 | September-October 2016, Volume 13, Issue 5
Dr. Cuker and Dr. George discuss a study that evaluates the safety, tolerability, and pharmacokinetics of SPK-9001 in subjects with hemophilia B.
- Heparin-Induced Thrombocytopenia: A Preventable Nosocomial DiseaseJune 08, 2016 | July-August 2016, Volume 13, Issue 4
Dr. Cuker studies options to reduce the incidence of HIT, treating it as a preventable nosocomial disease rather than an unavoidable iatrogenic disorder.
- Caplacizumab for TTP: A Temporizing Measure for a Relapsing DiseaseMarch 25, 2016 | May-June 2016, Volume 13, Issue 3
Dr. Cuker evaluates caplacizumab as a treatment for the relapse of patients with acquired thrombotic thrombocytopenic purpura (TTP).
- Flipping a Switch: Advances in DOAC Reversal in 2015January 11, 2016 | January-February 2016, Volume 13, Issue 1
Dr. Cuker discusses the continuous progress in the field of direct oral anticoagulants (DOAC) by looking at two studies that test the efficacy and safety of idarucizumab and andexanet alfa in patients with DOAC-associated bleeding.
- Turning the Tide on Dabigatran-Associated BleedingOctober 19, 2015 | November-December 2015, Volume 12, Issue 6
Dr. Cuker studies the use of idarucizumab, a monoclonal antibody fragment, to reverse the anticoagulant effect of dabigatran in bleeding patients.
- Pharmacomechanical Catheter-Directed Thrombolysis: An Attractive Option for Prevention of Post-Thrombotic Syndrome?June 03, 2015 | July-August 2015, Volume 12, Issue 4
Dr. Cuker looks at pharmacomechanical catheter-directed thrombolysis as an effective and safe strategy for the prevention of post-thrombotic syndrome.
- Factor XI Antisense: A Challenge to Common SenseFebruary 13, 2015 | March-April 2015, Volume 12, Issue 2
Dr. Cuker evaluates a study that shows targeting FXI is a rather effective antithrombotic therapy while challenging some commonly held misconceptions regarding the treatment.
- Long-Acting Factor Concentrates for Hemophilia January 08, 2015 | January-February 2015, Volume 12, Issue 1
Regular prophylactic factor infusion reduces bleeding, improves joint
health, and has become standard of care in the management of patients
with severe hemophilia A and B. However, the inconvenience of frequent
intravenous administration is an important source of patient
dissatisfaction and nonadherence. Most patients must infuse two to three
times weekly to maintain hemostatic trough levels due to the relatively
short half-lives of factor VIII (~12 hours) and factor IX (~20 hours).
The arrival of long-acting factor concentrate has been anxiously
anticipated as a means of enhancing the convenience of, and adherence
to, therapy. In 2014, long-acting factor IX concentrate arrived.
- A D-dimer Cutoff for
Excluding PE: One Size Does Not Fit AllSeptember 15, 2014 | September-October 2014, Volume 11, Issue 5
Dr. Cuker studies the approaches of diagnosing pulmonary embolisms.